CAN backs Laboratorios Ojer Pharma with €500,000
Corporación Caja Navarra (CAN), the private equity arm of Caja Navarra, has invested €500,000 in biotech company Laboratorios Ojer Pharma in return for a 11.22% in the business.
CAN's investment is part of a wider Navarre Investment Plan that will invest €20m in innovative and strategic entrepreneurial projects in the Navarre region.
Company
Launched in 2005 and based in Zizur Mayor, Laboratorios Ojer Pharma is a spin off from the University of Navarre. It currently has four products, which are in different phases of development - two of which are set to be authorised for commercialisation in the upcoming months. Other shareholders in the company are the Fundacion Universidad de Navarra and Clave Mayor through its funds Ronda Vida and Real de Vellon.
People
Javier Martinez Escudero represented CAN on the transaction. Carlos Gonzalez Ojer is the director of Laboratorios Ojer Pharma.
More on Southern Europe
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
EU FSR could impact PE fundraising with potential rise in ‘clean funds’
FSR could lead GPs to create funds without foreign LPs; red tape around sovereign wealth funds likely
Letter from the editor: Unquote is moving to Mergermarket
Unquote Editor Harriet Matthews outlines Unquote.com's upcoming move to the Mergermarket platform and the new capabilities and intelligence that this brings to Unquote readers
GP Profile: Apheon builds on family roots, mulls exits and reinvestment opportunities
Belgian GP, formerly known as Ergon, to continue to target family- and entrepreneur-owned European businesses
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater